Erasca (ERAS) Liabilities and Shareholders Equity (2020 - 2026)

Erasca (ERAS) posted Liabilities and Shareholders Equity of $461.2 million for Q1 2026, up 16.43% on a QoQ basis from $396.2 million in Q4 2025, and down 2.12% year-over-year from $471.2 million in Q1 2025.

Erasca (ERAS) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Erasca's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $461.2 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 2.12% year-over-year to $461.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (down 15.05% YoY) and the FY2025 annual result came in at $396.2 million, down 21.17% from the prior year.
  • Liabilities and Shareholders Equity was $461.2 million for Q1 2026 at Erasca, up from $396.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $528.9 million in Q3 2024 and bottomed at $370.0 million in Q1 2024.
  • A 5-year average of $454.5 million and a median of $446.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 111.43% — and 2023, when it slipped 23.23%.
  • Erasca's Liabilities and Shareholders Equity stood at $514.9 million in 2022, then declined by 23.23% to $395.3 million in 2023, then increased by 27.13% to $502.5 million in 2024, then dropped by 21.17% to $396.2 million in 2025, then gained by 16.43% to $461.2 million in 2026.
  • Business Quant data shows ERAS's Liabilities and Shareholders Equity at $461.2 million in Q1 2026, $396.2 million in Q4 2025, and $420.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Erasca 5.89 Bn 5.89 Bn - 461.23 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 461.23 Mn
Dec 31, 2025 396.15 Mn
Sep 30, 2025 420.40 Mn
Jun 30, 2025 445.39 Mn
Mar 31, 2025 471.24 Mn
Dec 31, 2024 502.53 Mn
Sep 30, 2024 528.90 Mn
Jun 30, 2024 525.74 Mn
Mar 31, 2024 370.02 Mn
Dec 31, 2023 395.30 Mn
Sep 30, 2023 419.41 Mn
Jun 30, 2023 440.66 Mn
Mar 31, 2023 467.54 Mn
Dec 31, 2022 514.91 Mn
Sep 30, 2022 446.43 Mn
Jun 30, 2022 444.82 Mn
Mar 31, 2022 475.47 Mn
Dec 31, 2021 501.42 Mn
Sep 30, 2021 521.95 Mn
Jun 30, 2021 210.38 Mn